Researchers at the Wharton School of the University of Pennsylvania have begun a pioneering study to determine whether GLP-1 drugs, such as Ozempic and Wegovy, can reduce impulsive behaviors like gambling and risky financial decisions. The study, funded by digital health company Noom, will run from mid-October 2024 to March 2027 and involves around 180 participants.
Examining the Brain’s Reward System
The research focuses on how GLP-1 medications, originally developed for weight loss and diabetes, might influence the brain’s reward circuitry. Participants will undergo MRI scans while performing tasks related to both food and financial choices. The aim is to observe whether GLP-1 use affects responses to immediate versus delayed rewards, such as choosing between a smaller sum of money now or a larger sum later.
Potential Implications for Financial Decision-Making
The Wharton team hypothesizes that GLP-1 drugs could dampen the urge for risky spending, including gambling and impulsive purchases, by altering how the brain processes reward and value. Previous studies have linked GLP-1s to reduced addictive behaviors, and the current research seeks to extend these findings to financial habits. If effective, the drugs could help individuals make more prudent financial choices, potentially shifting consumer behavior toward long-term savings over immediate gratification.
Why This Matters for the Gambling and iGaming Industry
If the study confirms that GLP-1 medications reduce the tendency to gamble or engage in speculative financial activities, it could have significant effects on the gambling and iGaming sectors. Operators and affiliates may see changes in player behavior, with a possible decrease in impulsive betting or spending. This could prompt companies to adapt their marketing strategies and responsible gambling measures, especially as public awareness of GLP-1’s broader effects grows.
Study Design and Next Steps
Participants will complete cognitive exercises and answer questions about their backgrounds and GLP-1 use. During MRI sessions, they will view images of spending opportunities and make real financial decisions, with outcomes that are later honored to ensure authentic responses. The study’s results, expected after March 2027, could offer new insights into the intersection of pharmacology, neuroscience, and consumer behavior.
Key takeaways
- Wharton researchers are investigating whether GLP-1 drugs reduce risky financial behaviors like gambling.
- The study involves MRI scans during decision-making tasks and will run through March 2027.
- Findings could impact how gambling operators and affiliates approach player engagement and responsible gaming.
- The research may reveal new ways to support healthier financial habits through medical intervention.